Miyamoto K, Ogino H, Kakimoto T, Matsumura Y, Haji K, Mitsuhashi A
Respir Med Case Rep. 2024; 51:102076.
PMID: 39027818
PMC: 11255952.
DOI: 10.1016/j.rmcr.2024.102076.
Wang H, Zhu Y, Sun W, Yang X, Liu X, Chi K
Cancers (Basel). 2023; 15(23).
PMID: 38067352
PMC: 10705092.
DOI: 10.3390/cancers15235649.
Hamilton G, Rath B
Cancer Drug Resist. 2022; 2(3):762-772.
PMID: 35582592
PMC: 8992524.
DOI: 10.20517/cdr.2019.47.
Calabrese F, Pezzuto F, Lunardi F, Fortarezza F, Tzorakoleftheraki S, Resi M
Int J Mol Sci. 2022; 23(8).
PMID: 35456982
PMC: 9031930.
DOI: 10.3390/ijms23084164.
Negri F, Bottarelli L, deAngelis G, Gnetti L
Int J Mol Sci. 2022; 23(8).
PMID: 35456940
PMC: 9027058.
DOI: 10.3390/ijms23084120.
Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis.
Xu J, Xu L, Wang B, Kong W, Chen Y, Yu Z
Front Oncol. 2022; 11:766148.
PMID: 35223450
PMC: 8867701.
DOI: 10.3389/fonc.2021.766148.
Significance of genetic sequencing in patients with lung adenocarcinoma with transformation to small cell lung cancer: a case report and systematic review.
Zhang C, Lin L, Guo X, Chen P
Transl Cancer Res. 2022; 9(5):3725-3733.
PMID: 35117735
PMC: 8798927.
DOI: 10.21037/tcr-19-2291.
Pathological transition as the arising mechanism for drug resistance in lung cancer.
Chen Y, Tang W, Tong X, Ji H
Cancer Commun (Lond). 2019; 39(1):53.
PMID: 31570104
PMC: 6771104.
DOI: 10.1186/s40880-019-0402-8.
Histologic transformation of non-small-cell lung cancer in brain metastases.
Jiang M, Zhu X, Han X, Jing H, Han T, Li Q
Int J Clin Oncol. 2018; 24(4):375-384.
PMID: 30443811
DOI: 10.1007/s10147-018-1369-1.
Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.
Shao Y, Zhong D
Int J Clin Oncol. 2017; 23(2):235-242.
PMID: 29110101
DOI: 10.1007/s10147-017-1211-1.
[Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors].
Zhang W, Li Y, Wu D
Zhongguo Fei Ai Za Zhi. 2017; 20(10):720-726.
PMID: 29061221
PMC: 5972996.
DOI: 10.3779/j.issn.1009-3419.2017.10.10.
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.
Ahn S, Hwang S, Han J, Choi Y, Lee S, Ahn J
J Pathol Transl Med. 2016; 50(4):258-63.
PMID: 27160687
PMC: 4963973.
DOI: 10.4132/jptm.2016.04.19.
Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors.
Shi X, Duan H, Liu X, Zhou L, Liang Z
Oncotarget. 2016; 7(23):34240-9.
PMID: 27145273
PMC: 5085152.
DOI: 10.18632/oncotarget.9083.
Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature.
Siegele B, Shilo K, Chao B, Carbone D, Zhao W, Ioffe O
Lung Cancer. 2016; 95:65-72.
PMID: 27040854
PMC: 5524560.
DOI: 10.1016/j.lungcan.2016.02.012.
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Jiang S, Zhao J, Wang M, Huo Z, Zhang J, Zhong W
Medicine (Baltimore). 2016; 95(6):e2752.
PMID: 26871823
PMC: 4753919.
DOI: 10.1097/MD.0000000000002752.
[Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma].
Xue S, Yu T, Zhang Y, Shan L
Zhongguo Fei Ai Za Zhi. 2015; 18(10):656-60.
PMID: 26483340
PMC: 6000092.
DOI: 10.3779/j.issn.1009-3419.2015.10.10.
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
Oser M, Niederst M, Sequist L, Engelman J
Lancet Oncol. 2015; 16(4):e165-72.
PMID: 25846096
PMC: 4470698.
DOI: 10.1016/S1470-2045(14)71180-5.
Prognostic and predictive biomarkers in lung cancer. A review.
Thunnissen E, Van der Oord K, den Bakker M
Virchows Arch. 2014; 464(3):347-58.
PMID: 24420742
DOI: 10.1007/s00428-014-1535-4.
